EDEN PRAIRIE, Minn., April 5, 2022 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective April 4, 2022, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”), as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.
In connection with entering into employment with NeuroOne, the individual, who was not previously an employee or director of NeuroOne, an option to purchase 1,000 shares of the Company’s common stock. The option award has an exercise price of $1.09 per share, the closing price of NeuroOne’s common stock on April 4, 2022, the date of the grant. The option has a ten-year term and vests as to 25% on April 1, 2023with the remaining shares vesting in equal monthly installments on the last day of each month over the next-six (36) months, provided the new hire’s employment is continuing on each such date.
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .
SOURCE NeuroOne Medical Technologies Corporation